BeiGene, Ltd.: BeiGene Reports First Quarter 2022 Financial

Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally

Related Keywords

China , Guangzhou , Guangdong , Australia , Japan , United States , United Kingdom , Suzhou , Jiangsu , Boston , Massachusetts , Princeton , Devon , Canada , South Korea , America , Chinese , Great Britain , American , Johnv Oyler , Kevin Mannix , Julia Wang , Emily Collins , Amgen , Virtual American Society Of Clinical Oncology , Beigene Ltd , Nasdaq , Novartis , Exchange Commission , Bio Thera Solutions Ltd , National Reimbursement Drug List , Ernst Young , American Academy For Cancer Research , European Union , Development Programs , European Medicines Agency , Princeton Innovation West , Independent Review Committee , Chief Financial Officer , Cash Equivalents , Restricted Cash , Short Term Investments , American Depositary Share , Virtual American Society , Clinical Oncology , Plenary Series , American Academy , Cancer Research , Annual Meeting , North America , Chimeric Degradation Activating Compound , Princeton West Innovation Campus , Change Is The , Leads Biolabs , Condensed Consolidated Balance Sheet Data , Consolidated Statements , American Depositary Shares , Months Ended , Private Securities Litigation Reform Act , Bio Thera Solutions , Beigene , Reports , First , Quarter , 022 , Financial , Results ,